• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

1992 Fiscal Year Final Research Report Summary

Isolation of osteoclast-forming factor produced by stromal cells and mechanism of osteoclast differentiation

Research Project

Project/Area Number 03670864
Research Category

Grant-in-Aid for General Scientific Research (C)

Allocation TypeSingle-year Grants
Research Field Functional basic dentistry
Research InstitutionTokyo Medical and Dental University

Principal Investigator

MORITA Ikuo  Tokyo Medical and Dental University Department of Dentistry, Associate Professor, 歯学部, 助教授 (60100129)

Project Period (FY) 1991 – 1992
Keywordsosteoclasts / Osteoblasts / adhesion molecules / stromal cells / cyclic AMP / stem cells
Research Abstract

I have succeeded to isolate the stromal cell line, which can support osteoclast formation from spleen cells and named as TMS-14 and 14. Using these stromal cells we studied the mechanism of osteoclast formation. As a result, osteoclast formation will be necessary for cAMP elevation in the stromal cells and an activation of A-kinase. And also the contact between spleen cells and stromal cells is also needed. Therefore, we next studied what adhesion molecule is important for osteoclast formation. In stromal cells ICAM-1 was expressed and in osteoclast progenitor cells LFA-1 and ICAM-1 were expressed. The antibodies for ICAM-1 and LFA-1 was added in the osteoclast formation system, the formation of osteoclast was significantly suppressed. However, the inhibition rate was only 50%. These results suggest that the other adhesion molecules was involved for osteoclast formation.
Stromal cells release osteoclast formation-stimulating factors as well as inhibiting factors. We failed to isolate the stimulators, but succeeded to characterize the inhibitory factors for osteoclast formation. The inhibitor was released from osteoblasts as well as stromal cells and the moleculr weight will be over 10000. The inhibitor can be regulated by some anti-osteoporosis drugs. This means that some drugs for osteoporosis affects via a production of this inhibitor for osteoclast formation.

  • Research Products

    (8 results)

All Other

All Publications (8 results)

  • [Publications] I.Morita et al: "Iprifavone inhibits murine osteoclast formation in vitro" Calcified Tissue International. 51. S7- 10 (1992)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] K.TORIYAMA et al.: "The existence of distinct classes of prostaglandin E2 receptors mediating adenylate cyclase and phospholipase C pathways in ostooblastic clone MC3T3-E1" Prostaglandin,Leukotriene and Essential Fattr Acids. 46. 15-21 (1992)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] KURACHI T et al.: "Involvement of adhesion molecules LFA-1 and ICAM-1 in osteoclast development" Biochim.Biophys Acta.

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 森田育男: "Bone Science講座[II]骨形式と骨吸収" 広川書店, 200 (1993)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] K. Toriyama, I. Morita, Y. Seyama, S. Yamashita, S. Murota: "Variation of increases in free cytosolic calcium ion induced by prostaglandin E2 in mouse osteoblast clone, MC3T3-E1" J. Bone and Mineral Research. 9. 34-38 (1991)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] I. Morita, K. Sakaguchi, T. Kurachi, S. Murota: "Ipriflavone inhibits murine osteoclast formation in vitro" Calcified Tissue International. 51. s7-s10 (1992)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] K. Toriyama, I. Morita, S. Murota: "The existence of distinct classes of prostaglandin E2 receptors mediating adenylate cyclase and phospholipase C pathways in osteoblastic clone MC3T3-E1" PG LT and EFA. 46. 15-20 (1992)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] T. Kurachi, I. Morita, S. Murota: "Involvement of adhesion molecules LFA-1 and ICAM-1 in osteoclast development" Biochim.Biophys.Acta.

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 1994-03-24  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi